Hemispherian, an Oslo, Norway-based preclinical pharmaceutical company, raised €10m in financing.
The financing included:
- €2.5M in grant funding
- €7.5M in equity financing from the European Innovation Council (EIC) Accelerator fund.
The company intends to use the funds to advance GLIX1, one of lead assets, through a phase I and phase II clinical trial.
Led by Adam Robertson, PhD, CSO, and Zeno Albisser, CEO, Chief Scientific Officer, Hemispherian is a pharmaceutical company focused on developing a small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company’s compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma, a deadly cancer of the central nervous system and the leading cause of death by disease in children.
FinSMEs
19/10/2022